Table 5 Univariate Cox regression for OS in the non-ASCT cohort according to the new risk stage
FDG parameter | New risk stage | HR (95% CI) | P value | Log-rank |
|---|---|---|---|---|
R-ISS + SUVmax | Overall | < 0.001 | ||
I vs. II | 2.148 (1.161–3.974) | 0.015 | ||
I vs. III | 9.617 (3.438–26.902) | < 0.001 | ||
II vs. III | 3.922 (1.459–10.540) | 0.007 | ||
R-ISS + SUVmean | Overall | < 0.001 | ||
I vs. II | 2.262 (1.211–4.223) | 0.010 | ||
I vs. III | 12.658 (4.487–35.713) | < 0.001 | ||
II vs. III | 5.423 (2.005–14.670) | < 0.001 | ||
R-ISS + MTV | Overall | 0.005 | ||
I vs. II | 2.806 (1.329–5.924) | 0.007 | ||
I vs. III | 3.929 (1.510–10.222) | 0.005 | ||
II vs. III | 1.399 (0.640–3.056) | 0.400 | ||
R-ISS + TLG | Overall | < 0.001 | ||
I vs. II | 2.888 (1.555–5.363) | < 0.001 | ||
I vs. III | 3.178 (1.272–7.941) | 0.013 | ||
II vs. III | 1.125 (0.453–2.796) | 0.799 | ||
R-ISS + FL | Overall | 0.014 | ||
I vs. II | 2.306 (1.190–4.468) | 0.013 | ||
I vs. III | 3.168 (1.201–8.358) | 0.020 | ||
II vs. III | 1.379 (0.568–3.349) | 0.478 |